| Webinar: Digitize Remote Site Monitoring with Box Tuesday, October 13 | 2pm ET / 11am PT Fierce Pharma is teaming up with Box to discuss how your life sciences organization can continue to propel therapies & devices through the value chain with faster and even more secure site monitoring and auditing. Accelerate R&D processes across the value chain, maintain GxP compliance and reduce your overall IT footprint. Save Your Spot! | Eli Lilly rushes to FDA with its COVID-19 antibody for emergency green light, reveals new cocktail therapy data Forget October. Warp Speed chief says first COVID shot data—from Pfizer and Moderna—won't appear till later this year Nearly 8M Americans in danger of losing job-based insurance, Commonwealth Fund analysis finds Gilead Sciences sends additional doses of COVID-19 therapy remdesivir to EU amid shortages Regeneron execs go on a whirlwind media tour after Trump takes COVID-19 antibody cocktail Hospitals that don't submit daily COVID-19 data could lose participation in Medicare, Medicaid Supply snags at Roche hit COVID-19 testing in the U.K.: Reuters Medtech CEOs discuss returning procedure volumes, V-shaped recoveries and 'the new normal' after COVID-19 CDRH's Shuren warns of the 'canary in the coal mine' in the FDA's COVID-19 response Biopharma roundup: Gilead ships extra remdesivir doses to shortage-hit EU; Roche hits U.K. testing supply snag: report 2020 breaks record in digital health investment with $9.4B in funding Israel's Mapi Pharma sets aside manufacturing space to boost country's COVID-19 jab supply Chinese COVID-19 vaccine trial reports falling antibody titers Featured Story By Ben Adams Eli Lilly is hustling to the FDA with its antibody therapy for a speedy emergency use authorization as it also reveals new data for a combo therapy. read more |
| |
---|
| Top Stories By Eric Sagonowsky President Donald Trump has repeatedly said a COVID-19 vaccine could be available around the election, but developments in recent days have all but nixed that possibility. Instead, officials are signaling a timeline of data releases that begins in November and continues into 2021, with emergency reviews along the way. read more By Robert King A new Commonwealth Fund study estimates as many as 7.7 million Americans could lose their employer-sponsored insurance due to job losses sparked by the COVID-19 pandemic. read more By Kyle Blankenship As one of few COVID-19 therapeutics with global regulators on board, Gilead Sciences' remdesivir saw immediate U.S. demand that has somewhat tapered off in recent months. But in the EU, some nations have seen spot shortages, and Gilead is stepping in with more supply. read more By Beth Snyder Bulik Just days after Regeneron published early data on its COVID-19 antibody cocktail, the White House announced that President Donald Trump was taking it. What followed was a run-up in Regeneron shares, repeated shout-outs from the president and a fair share of media appearances for the company's already high-profile execs. read more By Robert King Hospitals currently not reporting daily COVID-19 information could find themselves losing participation in Medicare and Medicaid. read more By Conor Hale A disruption in the supply chain of Roche’s U.K. division has constricted its shipments of COVID-19 tests and other diagnostic supplies throughout the country, according to a report from Reuters. read more By Conor Hale It’s an urgent question not only for the medtech community and its patients, but one described as “top of mind" for the healthcare industry at large: How will surgical procedures recover and evolve as the country continues to navigate the COVID-19 pandemic? read more By Conor Hale The FDA has found itself between overwhelming public demand for COVID-19 diagnostics, ventilators and other devices on one side, and a tsunami of companies submitting over 1,200 products for review on the other—and the workload is beginning to take its toll. read more By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner Gilead shipped extra remdesivir doses to the EU after reports of shortages. Roche hit testing supply snags in the U.K, Reuters reports. Regeneron has been riding a media wave ever since President Trump received the drugmaker's antibody cocktail. Plus, Nephron got hit with a warning letter for promoting an asthma drug to treat COVID-19 symptoms. read more By Heather Landi This year will be the largest funding year for digital health to date, with $9.4 billion invested up through the third quarter. Here's how much the sector is expected to hit by the end of the year. read more By Kyle Blankenship With the end of the year fast approaching, nations are looking for ways to secure enough supply of a potential COVID-19 vaccine to meet demand from their citizens. For Israeli drugmaker Mapi, meeting that demand means dedicating space at a Jerusalem facility to chip in on the effort. read more By Nick Paul Taylor The Chinese Academy of Medical Sciences has presented phase 1 data on its inactivated SARS-CoV-2 vaccine. The readout suggests the vaccine is safe and triggers an immune response, although a drop in neutralizing antibody titers from Day 14 to Day 28 is a potential cause for concern. read more |